ROIVANT SCIENCES LTD. Debt Instrument, Fee Amount
ROIVANT SCIENCES LTD. (ROIV) had Debt Instrument, Fee Amount of $4.00 million as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFeeAmount · last filed 2022-06-28
- 2021-09-30: Debt Instrument, Fee Amount $4.00M.
- 2021-05-31: Debt Instrument, Fee Amount $4.00M.
- 2019-05-31: Debt Instrument, Fee Amount $1.40M.
| Period end | Debt Instrument, Fee Amount |
|---|---|
| 2021-09-30 | $4.00M 10-Q · filed 2021-11-15 |
| 2021-05-31 | $4.00M 10-K · filed 2022-06-28 |
| 2019-05-31 | $1.40M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |